John Murphy, M.D., M.P.H., D.P.H. Covid-19LOng-haul Foundation
Abstract
Post‑acute sequelae of SARS‑CoV‑2 infection (PASC), commonly known as long‑COVID, is a multisystem disorder affecting 10–20% of patients following acute infection. Among its varied manifestations, peripheral nerve neuropathy—particularly small‑fiber neuropathy (SFN)—has emerged as a frequent, disabling sequela characterized by pain, paresthesia, and dysautonomia. Evidence suggests that peripheral neuropathy following COVID‑19 results not from direct viral persistence but from post‑infectious immune dysregulation, autonomic dysfunction, and inflammatory processes. Objective neurophysiologic and histologic studies demonstrate SFN in long‑COVID cohorts, implicating immune mechanisms and sometimes autoantibodies. This paper reviews current knowledge on etiology, genomic susceptibility, immunopathology, physiological mechanisms, diagnostic strategies, and clinical treatment paradigms for long‑COVID–associated neuropathy, with an emphasis on multidisciplinary insights and immunologic underpinnings.
Introduction
The clinical syndrome of long‑COVID encompasses a broad range of persistent symptoms lasting beyond 12 weeks after acute SARS‑CoV‑2 infection. These include fatigue, cognitive impairment (“brain fog”), pain, and autonomic dysfunction. Peripheral neuropathic symptoms—particularly burning pain, numbness, and autonomic disturbances—are increasingly recognized and frequently linked to small‑fiber neuropathy (SFN). A 2024 case‑control study found that approximately 50% of patients with painful long‑COVID met diagnostic criteria for SFN on quantitative sensory testing or skin biopsy.
Peripheral nerve involvement in PASC is not restricted to large‑fiber neuropathy; indeed, small unmyelinated (C) and thinly myelinated (Aδ) fibers mediating pain and autonomic function are often implicated, resulting in both sensory and autonomic symptoms ranging from burning pain to orthostatic intolerance.
Etiology
Post‑Infectious Immune Dysregulation
Evidence strongly suggests that peripheral neuropathy in long COVID is predominantly immune‑mediated rather than due to persistent viral replication. Data from peripheral neuropathy evaluations show that patients with PASC often lack antecedent risk factors for neuropathy yet develop symptoms within weeks of acute SARS‑CoV‑2 infection.
Post‑infectious immune dysregulation may involve aberrant activation of both innate and adaptive immune pathways. Several studies describe inflammatory markers in a substantial proportion of PASC patients. Moreover, autoantibodies isolated from long‑COVID patients—when passively transferred to mice—induce neurological deficits, including small fiber damage, indicating the potential for autoimmune mechanisms in neuropathy pathogenesis.
Microvascular and Endothelial Injury
SARS‑CoV‑2–induced endothelial dysfunction and microvascular injury could contribute to ischemic damage of peripheral nerve fibers. Although direct viral invasion of nerves is less convincingly demonstrated, vascular dysregulation and low‑grade inflammation affecting the vasa nervorum may compromise nerve perfusion, exacerbating neuropathic symptoms.
Autonomic Dysregulation
Small nerve fibers play key roles in autonomic regulation (heart rate, sweating, GI motility). In PASC, dysautonomia (e.g., postural orthostatic tachycardia syndrome [POTS]–like symptoms) is frequently observed, often overlapping with SFN. A study found cerebrovascular and autonomic dysregulation in PASC patients similar to POTS patients, highlighting overlapping pathophysiology involving small fiber and autonomic dysfunction.
Genomics and Host Susceptibility
Genetic predisposition may influence the risk of developing long‑COVID neuropathy. Variants in HLA loci and genes involved in immune regulation could predispose individuals to persistent post‑infectious immune activation and autoimmunity. Although detailed genomic studies specifically addressing PASC‑associated neuropathy are still emergent, broader genomic analyses implicate host factors in long COVID susceptibility, including pathways related to immune signaling and inflammation.
Emerging work on long COVID proteomic and network analyses identifies mitochondrial dysfunction, thromboinflammatory pathways, and neural inflammation as important factors, suggesting that genetic and molecular regulation of immune and inflammatory networks may contribute to neuropathy.
Immunopathology
Immune Cell Activation and Cytokine Signatures
In PASC, persistent low‑grade inflammation can involve elevated cytokines and immune cell activation. While heterogeneity exists, elevated inflammatory markers have been observed in many PASC cohorts, implying ongoing immune system perturbations.
Autoantibodies
Autoantibody production post‑SARS‑CoV‑2 infection may contribute to neuropathic processes. The transfer of IgG from long‑COVID patients to animal models produced neurological symptoms and small fiber nerve damage, suggesting pathogenic autoantibodies targeting peripheral nerve elements.
Molecular Mimicry
SARS‑CoV‑2 shares peptide sequences with host proteins, positing a mechanism of molecular mimicry that could trigger autoimmune responses against peripheral nerve components, although direct evidence linking specific mimics to SFN in long COVID is still under investigation.
Pathology and Physiological Mechanisms
Small Fiber Pathology
SFN involves damage to thinly myelinated Aδ and unmyelinated C fibers, disrupting nociception and autonomic regulation. Skin biopsy studies from long‑COVID patients show reduced intraepidermal nerve fiber density in a large proportion of cases while nerve conduction studies often remain normal, reflecting selective small fiber involvement.
Neurophysiological Alterations
Quantitative sensory testing (QST) and laser evoked potentials can reveal sensory dysfunction corresponding to SFN. These objective measures complement histological findings, and in some cohorts QST shows high sensitivity for detecting small fiber damage.
Autonomic Nervous System Dysfunction
SFN often co‑exists with autonomic abnormalities such as orthostatic intolerance, heart rate variability changes, and sudomotor dysfunction. Such symptoms reflect disruption of small fibers innervating autonomic targets and may manifest independent of detectable sensory neuropathy on standard tests.
Clinical Presentation
Patients with long‑COVID–associated neuropathy commonly report burning pain, paresthesias, numbness, and dysesthesia affecting distal extremities, often accompanied by autonomic symptoms (palpitations, GI dysmotility, orthostatic intolerance). Symptoms may vary in distribution and severity and often persist for months. Full thickness skin biopsy remains the diagnostic gold standard for SFN, with quantitative sensory testing and autonomic function testing supportive.
Diagnostics
- Skin Punch Biopsy: Measures intraepidermal nerve fiber density and is the most specific test for SFN.
- Quantitative Sensory Testing (QST): Assesses perception thresholds for thermal and pain stimuli, useful for functional evaluation.
- Autonomic Function Testing: Tilt table testing, sudomotor assessments, and heart rate variability analyses assess autonomic involvement.
- Electrodiagnostic Studies: Often normal in pure SFN due to sparing of large fibers.
Clinical Treatment
Symptomatic Management
Neuropathic pain is commonly treated with FDA‑approved agents such as gabapentinoids, SNRIs (duloxetine), and TCAs (nortriptyline), tailored to symptom severity and patient tolerability.
Immunomodulatory Therapies
Emerging case series suggest that immunotherapies—corticosteroids, intravenous immunoglobulin (IVIG), and plasmapheresis—may benefit subsets of patients with suspected immune‑mediated SFN. In one cohort of PASC neuropathy patients, 65% received immunotherapies with partial improvements documented. Controlled clinical trials are lacking, but immunomodulation is often considered when symptoms are severe and immune markers are present.
Rehabilitation and Supportive Care
Physical therapy, pain rehabilitation programs, and autonomic retraining can improve functional status. Psychological support is critical given the chronic nature of symptoms.
Emerging and Experimental Strategies
Targeted therapies addressing specific immune pathways (e.g., B‑cell depletion, cytokine blockade) remain under investigation. Genetic and biomarker profiling may in future allow more personalized approaches.
Prognosis and Outcomes
Long‑COVID neuropathy exhibits variable trajectories. Some patients improve over 6–12 months with supportive care and targeted therapy, while others experience persistent symptoms. Longitudinal studies indicate that symptoms can gradually ameliorate, but many individuals continue to suffer chronic pain and dysautonomia beyond a year.
Future Directions
Research priorities include:
- Large genomic studies to identify susceptibility loci.
- Controlled clinical trials for immunotherapy in SFN post‑COVID.
- Biomarker discovery for early diagnosis and treatment stratification.
- Integrative mechanistic studies connecting immune dysregulation, autoantibodies, and nerve pathology.
Conclusion
Peripheral neuropathy—especially small‑fiber involvement—is a significant component of PASC, driven predominantly by post‑infectious immune mechanisms and dysautonomia rather than persistent viral infection. Multidisciplinary evaluation including immunology, neurophysiology, and pathology is key to diagnosis and management. Although evidence for targeted treatments such as immunomodulation is emerging, further controlled studies are imperative to optimize outcomes.
References
- Pietro Falco, et al. Small fibre neuropathy frequently underlies the painful long‑COVID syndrome. Pain. 2024;165(9):2002‑2010. doi:10.1097/j.pain.0000000000003259.
- Drobinska N, et al. Small Fiber Neuropathy in Long COVID: A Cohort Study with Multimodal Assessment and Follow‑Up. Eur Neurol. 2025;88(2):52‑63.
- Abrams RMC, Simpson DM, Navis A, et al. Small Fiber Neuropathy associated with SARS‑CoV‑2 infection. Muscle Nerve. 2022;65(4):440‑443.
- Oaklander AL, et al. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID. Neurol Neuroimmunol Neuroinflamm. 2022;9(3):e1146.
- Postacute Sequelae of SARS‑CoV‑2 Infection and Implications for Recovery. NCBI Bookshelf.
- Autoantibodies from Long COVID patients trigger CNS and PNS symptoms in mice. J Immunol.